147 related articles for article (PubMed ID: 21910085)
1. Glycosphingolipids and insulin resistance.
Aerts JM; Boot RG; van Eijk M; Groener J; Bijl N; Lombardo E; Bietrix FM; Dekker N; Groen AK; Ottenhoff R; van Roomen C; Aten J; Serlie M; Langeveld M; Wennekes T; Overkleeft HS
Adv Exp Med Biol; 2011; 721():99-119. PubMed ID: 21910085
[TBL] [Abstract][Full Text] [Related]
2. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
Bijl N; Sokolović M; Vrins C; Langeveld M; Moerland PD; Ottenhoff R; van Roomen CP; Claessen N; Boot RG; Aten J; Groen AK; Aerts JM; van Eijk M
Hepatology; 2009 Nov; 50(5):1431-41. PubMed ID: 19731235
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity.
Aerts JM; Ottenhoff R; Powlson AS; Grefhorst A; van Eijk M; Dubbelhuis PF; Aten J; Kuipers F; Serlie MJ; Wennekes T; Sethi JK; O'Rahilly S; Overkleeft HS
Diabetes; 2007 May; 56(5):1341-9. PubMed ID: 17287460
[TBL] [Abstract][Full Text] [Related]
4. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity.
Samad F; Badeanlou L; Shah C; Yang G
Adv Exp Med Biol; 2011; 721():67-86. PubMed ID: 21910083
[TBL] [Abstract][Full Text] [Related]
5. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.
Ilan Y
Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G1102-17. PubMed ID: 27173510
[TBL] [Abstract][Full Text] [Related]
6. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation.
van Eijk M; Aten J; Bijl N; Ottenhoff R; van Roomen CP; Dubbelhuis PF; Seeman I; Ghauharali-van der Vlugt K; Overkleeft HS; Arbeeny C; Groen AK; Aerts JM
PLoS One; 2009; 4(3):e4723. PubMed ID: 19305508
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
8. Glycosphingolipids and insulin resistance.
Langeveld M; Aerts JM
Prog Lipid Res; 2009; 48(3-4):196-205. PubMed ID: 19303901
[TBL] [Abstract][Full Text] [Related]
9. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
Lachmann RH
Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
[TBL] [Abstract][Full Text] [Related]
10. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
11. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
12. Glycosphingolipids and kidney disease.
Mather AR; Siskind LJ
Adv Exp Med Biol; 2011; 721():121-38. PubMed ID: 21910086
[TBL] [Abstract][Full Text] [Related]
13. Sphingolipids and hepatic steatosis.
Bikman BT; Summers SA
Adv Exp Med Biol; 2011; 721():87-97. PubMed ID: 21910084
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice.
Bietrix F; Lombardo E; van Roomen CP; Ottenhoff R; Vos M; Rensen PC; Verhoeven AJ; Aerts JM; Groen AK
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):931-7. PubMed ID: 20167657
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes.
Zhao H; Przybylska M; Wu IH; Zhang J; Siegel C; Komarnitsky S; Yew NS; Cheng SH
Diabetes; 2007 May; 56(5):1210-8. PubMed ID: 17470562
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.
Zhao H; Przybylska M; Wu IH; Zhang J; Maniatis P; Pacheco J; Piepenhagen P; Copeland D; Arbeeny C; Shayman JA; Aerts JM; Jiang C; Cheng SH; Yew NS
Hepatology; 2009 Jul; 50(1):85-93. PubMed ID: 19444873
[TBL] [Abstract][Full Text] [Related]
17. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?
Shayman JA
Trans Am Clin Climatol Assoc; 2013; 124():46-60. PubMed ID: 23874009
[TBL] [Abstract][Full Text] [Related]
18. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
Nestel PJ; Mensink RP
Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
[TBL] [Abstract][Full Text] [Related]
19. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.
den Boer M; Voshol PJ; Kuipers F; Havekes LM; Romijn JA
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):644-9. PubMed ID: 14715643
[TBL] [Abstract][Full Text] [Related]
20. Hepatic glycosphingolipid deficiency and liver function in mice.
Jennemann R; Rothermel U; Wang S; Sandhoff R; Kaden S; Out R; van Berkel TJ; Aerts JM; Ghauharali K; Sticht C; Gröne HJ
Hepatology; 2010 May; 51(5):1799-809. PubMed ID: 20432257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
